Finepoint Capital LP Has $18.56 Million Holdings in Galapagos NV (NASDAQ:GLPG)

Finepoint Capital LP lifted its holdings in Galapagos NV (NASDAQ:GLPG) by 21.0% during the 4th quarter, Holdings Channel.com reports. The firm owned 674,762 shares of the biotechnology company’s stock after buying an additional 117,000 shares during the period. Galapagos makes up about 1.1% of Finepoint Capital LP’s investment portfolio, making the stock its 10th largest position. Finepoint Capital LP’s holdings in Galapagos were worth $18,556,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. R Squared Ltd bought a new position in Galapagos in the fourth quarter worth approximately $26,000. GAMMA Investing LLC raised its holdings in Galapagos by 77.4% in the 4th quarter. GAMMA Investing LLC now owns 2,233 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 974 shares during the period. QRG Capital Management Inc. raised its holdings in Galapagos by 21.7% in the 4th quarter. QRG Capital Management Inc. now owns 10,455 shares of the biotechnology company’s stock worth $288,000 after purchasing an additional 1,866 shares during the period. American Century Companies Inc. lifted its position in Galapagos by 5.9% during the fourth quarter. American Century Companies Inc. now owns 25,852 shares of the biotechnology company’s stock valued at $711,000 after purchasing an additional 1,431 shares in the last quarter. Finally, Crossmark Global Holdings Inc. grew its holdings in Galapagos by 31.5% during the fourth quarter. Crossmark Global Holdings Inc. now owns 49,163 shares of the biotechnology company’s stock valued at $1,352,000 after purchasing an additional 11,777 shares during the period. Hedge funds and other institutional investors own 32.46% of the company’s stock.

Analysts Set New Price Targets

GLPG has been the topic of a number of analyst reports. Morgan Stanley cut Galapagos from an “equal weight” rating to an “underweight” rating and lowered their price objective for the company from $31.00 to $22.00 in a research report on Friday, February 14th. Barclays reiterated an “underweight” rating on shares of Galapagos in a research note on Thursday, January 23rd. Finally, TD Cowen downgraded Galapagos from a “strong-buy” rating to a “strong sell” rating in a research report on Thursday, January 9th. Four research analysts have rated the stock with a sell rating and four have assigned a hold rating to the stock. Based on data from MarketBeat, Galapagos currently has a consensus rating of “Hold” and a consensus target price of $25.33.

Galapagos Trading Down 1.5 %

GLPG stock opened at $23.75 on Friday. The company has a fifty day simple moving average of $25.13 and a two-hundred day simple moving average of $26.73. Galapagos NV has a 52 week low of $22.36 and a 52 week high of $32.17.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.